细胞选择性靶向嵌合体(SelecTACB)在B细胞上降解膜蛋白

IF 15.6 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Zhenlin Yang, , , Jianfei Jiang, , , Yuhui Cao, , , Haoming Fang, , , Xianrui Zhang, , , Yuxuan Zhang, , , Heng Zhang*, , and , Peng R. Chen*, 
{"title":"细胞选择性靶向嵌合体(SelecTACB)在B细胞上降解膜蛋白","authors":"Zhenlin Yang,&nbsp;, ,&nbsp;Jianfei Jiang,&nbsp;, ,&nbsp;Yuhui Cao,&nbsp;, ,&nbsp;Haoming Fang,&nbsp;, ,&nbsp;Xianrui Zhang,&nbsp;, ,&nbsp;Yuxuan Zhang,&nbsp;, ,&nbsp;Heng Zhang*,&nbsp;, and ,&nbsp;Peng R. Chen*,&nbsp;","doi":"10.1021/jacs.5c09630","DOIUrl":null,"url":null,"abstract":"<p >Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTAC<sup>B</sup> as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTAC<sup>B</sup> allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTAC<sup>B</sup> can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.</p>","PeriodicalId":49,"journal":{"name":"Journal of the American Chemical Society","volume":"147 40","pages":"36301–36309"},"PeriodicalIF":15.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells\",\"authors\":\"Zhenlin Yang,&nbsp;, ,&nbsp;Jianfei Jiang,&nbsp;, ,&nbsp;Yuhui Cao,&nbsp;, ,&nbsp;Haoming Fang,&nbsp;, ,&nbsp;Xianrui Zhang,&nbsp;, ,&nbsp;Yuxuan Zhang,&nbsp;, ,&nbsp;Heng Zhang*,&nbsp;, and ,&nbsp;Peng R. Chen*,&nbsp;\",\"doi\":\"10.1021/jacs.5c09630\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTAC<sup>B</sup> as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTAC<sup>B</sup> allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTAC<sup>B</sup> can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.</p>\",\"PeriodicalId\":49,\"journal\":{\"name\":\"Journal of the American Chemical Society\",\"volume\":\"147 40\",\"pages\":\"36301–36309\"},\"PeriodicalIF\":15.6000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Chemical Society\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/jacs.5c09630\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Chemical Society","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/jacs.5c09630","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

膜蛋白降解嵌合体(MPDs)扩大了当前靶向蛋白降解技术(TPDs)的应用空间,但细胞选择性的膜蛋白降解嵌合体(MPDs)仍然缺乏,特别是免疫细胞表面蛋白。当目标蛋白在多种免疫细胞类型中表达时,在特定细胞类型上精确降解是具有挑战性的。在这里,我们介绍SelecTACB作为靶向膜蛋白降解嵌合体,在B细胞上具有选择性。SelecTACB利用CD22作为B细胞特异性溶酶体靶向受体诱导内吞作用和溶酶体降解,使膜蛋白以靶向和细胞选择性的方式降解。我们发现SelecTACB可以有效地降解人外周血单核细胞(PBMCs) B细胞上的CD40和ICOSL等指定蛋白,而不影响其他免疫细胞类型的蛋白表达。参与T细胞刺激途径的关键蛋白的降解导致B细胞功能的持续抑制。总之,我们的工作建立了一个细胞类型选择性降解平台,为免疫细胞的靶向膜蛋白降解提供了一般策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells

Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells

Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells

Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTACB as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTACB allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTACB can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
24.40
自引率
6.00%
发文量
2398
审稿时长
1.6 months
期刊介绍: The flagship journal of the American Chemical Society, known as the Journal of the American Chemical Society (JACS), has been a prestigious publication since its establishment in 1879. It holds a preeminent position in the field of chemistry and related interdisciplinary sciences. JACS is committed to disseminating cutting-edge research papers, covering a wide range of topics, and encompasses approximately 19,000 pages of Articles, Communications, and Perspectives annually. With a weekly publication frequency, JACS plays a vital role in advancing the field of chemistry by providing essential research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信